



We're proud to announce that Novugen has officially entered into a commercial agreement with Hikma Pharmaceuticals PLC, for Novugen's USFDA-approved Abbreviated New Drug Application (ANDA) for trametinib tablets. Under this agreement, Novugen will manufacture and supply the product, while Hikma will take the lead in sales and marketing across the US. This milestone will strengthen our impact in high-barrier, niche pharmaceutical segments and reinforce our commitment to improving global access to life-saving treatments.

Novugen CEO, Rahil Mahmood, emphasized that this partnership reflects Novugen's dedication to innovation, regulatory excellence, and making complex, cost-efficient oncology products more accessible to patients in need. As we continue to break barriers in the pharmaceutical industry, partnerships like this reflect our vision of creating a healthier world by making critical treatments accessible to those who need them most.

[\[Click here\]](#) to read the full press release on Hikma's official website below.